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Background. Recent studies have shown that fish oil, con-
taining x-3 polyunsaturated fatty acids (x-3 PUFAs) eicos-
apentaenoic acid (EPA) (C20:5 x 3), and docosahexaenoic
acid (DHA) (C22:6 x 3) retard the progression of renal dis-
ease, especially in IgA nephropathy (IgAN). Despite increasing
knowledge of the beneficial effects of fish oils, little is known
about the mechanisms of action of x-3 PUFAs. It has been
reported that activation of peroxisome proliferator-activated
receptors (PPARs) inhibits production of proinflammatory cy-
tokines. Both EPA and DHA have been shown to activate
PPARs. The aim of this study was to examine if x-3 PUFAs
have anti-inflammatory effects via activation of PPARs in hu-
man renal tubular cells.
Methods. An immortalized human proximal tubular cell line
[human kidney-2 (HK-2) cells] was used in all experiments.
Conditioned media was collected from x-3 PUFAs- treated
cells and subjected to enzyme-linked immunosorbent assay
(ELISA). Total cellular RNA was isolated from the above cells
for real-time quantitative polymerase chain reaction (PCR).
Nuclear Extracts were prepared from the HK-2 cells for tran-
scription factor activation assay.
Results. Both EPA and DHA at 10 lmol/L and 100 lmol/L
concentrations effectively decreased lipopolysaccharide (LPS)-
induced nuclear factor-kappaB (NF-jB) activation and mono-
cyte chemoattractant protein-1 (MCP-1) expression. EPA and
DHA also increased both PPAR-c mRNA and protein activity
(two- to threefold) in HK-2 cells. A dose of 100 lmol/L bisphe-
nol A diglycidyl ether (BADGE) abolished the PPAR-c activa-
tion induced by both EPA and DHA and removed the inhibitory
effect of EPA and DHA on LPS-induced NF-jB activation in
HK-2 cells. Overexpression of PPAR-c further inhibited NF-jB
activation compared to the control cells in the presence of EPA
and DHA.
Conclusion. Our data demonstrate that both EPA and DHA
down-regulate LPS-induced activation of NF-jB via a PPAR-
c–dependent pathway in HK-2 cells. These results suggest that
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PPAR-c activation by EPA and DHA may be one of the under-
lying mechanisms for the beneficial effects of fish oil.
Consumption of fish oil containing high levels of x-3
polyunsaturated fatty acids(x-3 PUFAs) such as eicos-
apentaenoic acid (EPA) (C20:5 x 3) and docosahex-
aenoic acid (DHA) (C22:6 x 3) has been reported to
improve the prognosis of several chronic inflammatory
diseases, including atherosclerosis, systemic lupus ery-
thematosus, psoriasis, inflammatory bowel disease, and
rheumatoid arthritis [1–4]. Recent studies have shown
that administration of x-3 PUFA reduces proteinuria and
ameliorates renal injury in murine lupus nephritis, ex-
perimental focal segmental glomerulosclerosis, and other
types of renal diseases [5–9]. In IgA nephropathy (IgAN),
the most common glomerulonephritis worldwide, renal
disease progression was markedly reduced in patients
given a fish oil supplement containing EPA and DHA
[10–12].
While the potential beneficial effects of dietary fish
oil are reasonably well documented, the mechanism by
which disease manifestations are suppressed remains un-
known [13]. The accumulation of macrophages within the
interstitial space of the renal cortex plays a pathogenic
role in the development of tubular injury and intersti-
tial fibrosis in progressive chronic renal diseases [14, 15].
Proximal tubular epithelial cells (PTC) are thought to
mediate the interstitial macrophage infiltration because
of their anatomic proximity and ability to produce proin-
flammatory mediators and chemotactic cytokines such
as monocyte chemoattractant protein-1 (MCP-1), which
have an important role in the regulation of interstitial
inflammation and other processes related to matrix de-
position [16]. In PTC, the ubiquitous proinflammatory
transcription factor nuclear factor-kappaB (NF-jB) has
a pivotal role in the regulation of chemokines (MCP-
1), adhesion molecules [intracellular adhesion molecule-
1 (ICAM-1)], cytokines [such as interleukin (IL)-1 and
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tumor necrosis factor-a (TNF-a)] and many early re-
sponse genes [17].
Peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear hormone receptor super-
family of ligand-dependent transcription factors. They
play an important role in the general transcriptional
control of numerous cellular processes, including lipid
metabolism, glucose homeostasis, cell cycle progression,
cell differentiation, inflammation, and extracellular ma-
trix remodeling [18]. Known PPAR isoforms include
PPAR-a, implicated in fatty acid metabolism, PPAR-c,
important in lipoprotein metabolism, adipogenesis, and
insulin sensitivity, and PPAR-b/d about which least is
known. Synthetic PPAR-a ligands such as fibrates, for
example, fenofibric acid, is used therapeutically to lower
triglyceride-rich lipoproteins [19]. Synthetic PPAR-c lig-
ands such as thiazolidinediones (for example, rosiglita-
zone) are insulin-sensitizing drugs used in the treatment
of diabetes [20]. Recent studies suggest that PPAR lig-
ands may reduce the inflammatory response by attenuat-
ing the production of proinflammatory cytokine [21]. x-3
PUFAs such as EPA and DHA are known natural ligands
of PPARs, although they are required in relatively high
concentrations (approximately 100 lmol/L) for PPAR ac-
tivation and are not selective for PPAR subtypes. Their
derivatives can further activate PPAR. For example, a cy-
clooxygenase product of arachidonic acid, 15d-12,14-
prostaglandin J2 (PGJ2), is a selective PPAR-c ligand,
whereas its lipoxygenase product, 8(S)hydroxy-(5Z,9E,
11Z,14Z)-eicosatetraenoic acid (HETE), is a selective
PPAR-a ligand [22–24].
Since fatty acids are natural PPAR ligands, we hypothe-
sized that x-3 PUFAs EPA and DHA may inhibit NF-jB
activation and MCP-1 expression in a human PTC cells
line through PPAR activation.
METHODS
Preparation of fatty acids
EPA and DHA were purchased from Sigma Chemical
Co. Ltd (Dorset, UK), resuspended in absolute ethanol
and added to a 0.3 mmol/L solution of essential fatty acid–
free bovine serum albumin (BSA) in phosphate-buffered
saline (PBS). Solutions were aliquoted and frozen. The
vehicle control for EPA and DHA was 0.3 mmol/L so-
lution of essential fatty acid–free BSA in PBS plus ab-
solute ethanol. Bisphenol A diglycidyl ether (BADGE)
was purchased from Tocris (Ballwin, MO, USA).
Cell culture
Human kidney-2 (HK-2) cells, an immortalized hu-
man PTC line, was purchased from American Type Cul-
ture Collection (Mannasas, VA, USA) [25]. The cells
were grown in keratinocyte serum-free media (K-SFM)
(Invitrogen, Paisley, UK) supplemented with bovine pi-
tuitary extract (40 lg/mL) and epidermal growth fac-
tor (5 ng/mL). The cell lines were complemented with
2 mmol/L glutamine, 100 U/mL penicillin, and 100 lg/mL
streptomycin and maintained in a 37◦C, 5% CO2 humid-
ified atmosphere. Cultures were refed with fresh media
every 2 to 3 days. Experiments were performed on cells
following a 24-hour incubation in the medium used for
experiments which consisted of keratinocyte serum-free
medium without bovine pituitary extract (40 lg/mL) and
epidermal growth factor (5 ng/mL). Cells were incubated
with various concentrations of x-3 PUFAs such as EPA
and DHA in the presence or absence of lipopolysaccha-
ride (LPS) for 24 hours. The conditioned media and cells
were collected for analysis.
RNA isolation and real-time quantitative reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from cultured HK-2 cells by
the guanidinium method. Total RNA (500 ng) was used
as a template for RT using an RNA RT Kit from ABI
(Applied Biosystems Ltd., Warrington, Cheshire, UK).
The RT reaction was set up in a 20 lL mixture con-
taining 50 mmol/L KCl, 10 mmol/L Tris/HCl, 5 mmol/L
MgCl2, 1 mmol/L of each deoxynucleoside triphosphate
(dNTP), 2.5 lmol/L random hexamers, 20 U RNAsin,
and 50 U of Moloney-murine leukemia virus (M-MLV)
reverse transcriptase. Incubations were performed in a
DNA Thermal Cycler 9700 (Applied Biosystems, Foster
City, CA, USA) for 10 minutes at room temperature,
followed by 30 minutes at 42◦C and 5 minutes at 99◦C.
Real-time quantitative PCR was performed on a TaqMan
ABI 7000 Sequence Detection System (Applied Biosys-
tems) using TaqMan SybrGreen PCR Master Mix (Ap-
plied Biosystems). Thermal Cycler conditions contained
holds for 2 minutes at 50◦C and 10 minutes at 95◦C, fol-
lowed by 40 cycles of 20 seconds at 95◦C and 20 sec-
onds at 55◦C and 30 seconds at 72◦C. Relative amount
of mRNA was calculated using comparative Ct (Ct)
method. b-actin served as the reference housekeeping
gene. The amplification efficiencies of the target and ref-
erence were shown to be approximately equal with a
slope of log input amount to Ct <0.1. Controls consisting
of H2O or samples that were not RT were negative for tar-
get and reference. The following oligonucleotide primers
were used for MCP-1 sense (975–996) 5′-TGTTCT
TCGAAAGCACATCAC-3′ and antisense (1023–1046),
5′-GTAGGTGACAGAGGGACATCT-TTT–3′, melting
temperature (TM) = 79◦C; PPAR-c sense (807–
824) 5′-GGGCCCTGGCAAAACATT-3′ and antisense
(865–872) 5′-AAGATCGCCCTCGCCTTT-3′, TM =
80◦C; and b-actin sense (1030–1047) 5′-CCTGG
CACCCAGCACAAT-3′ and antisense (1080–1099)
5′-GCCG-ATCCACACGGAGTACT-3′, TM = 82◦C.
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Primers were designed with Primer Express Software ver-
sion 2.0 System (Applied Biosystems, Foster City, CA,
USA).
MCP-1 assays
Culture supernatant was collected from 24-well plates
and concentrations of MCP-1 measured by enzyme-
linked immunosorbent assay (ELISA) using protocols
supplied by the manufacturer (R&D Systems, Abingdon,
UK) and normalized to cell protein concentrations.
Preparation of nuclear extracts
Confluent HK-2 cells in T75 flasks were washed with
5 mL PBS/phosphatase inhibitors, the supernatant as-
pirated and 3 mL ice-cold PBS/phosphatase inhibitors
added. Cells were removed by gently scraping with a
cell lifter and transferred to a prechilled 15 mL conical
tube. The cell suspension was centrifuged for 5 minutes
at 500 rpm in a centrifuge precooled at 4◦C and the super-
natant discarded. A Nuclear Extract Kit (Active Motif,
Rixensart, Belgium) was used for isolation of nuclear ex-
tracts from cell pellets, according to the manufacturer’s
instructions.
Trans-AM PPAR-c and NF-jB p65 transcription
factor assay
The Trans-AM PPAR-c Kit contains a 96-well plate
on which an oligonucleotide containing a peroxi-
some proliferator response element (PPRE) (5′-AACTA
GGTCAAAGGTCA-3′) has been immobilized. PPAR-c
contained in nuclear extract specifically binds to this
oligonucleotide. The primary antibody used in the Trans-
AM PPAR-c Kit recognizes an accessible epitope on
PPAR-c protein upon DNA binding. Addition of a sec-
ondary horseradish peroxidase (HRP)-conjugated an-
tibody provides a sensitive colorimetric readout easily
quantified by spectrophotometry. To quantify PPAR-c ac-
tivation, 5 lg of nuclear extract was measured using the
Trans-AM PPARc Kit according to the manufacturer’s
instructions (Active Motif).
The Trans-AM NF-jB p65 kits contain a 96-well plate
on which oligonucleotide containing the NF-jB consen-
sus site (5′-GGGACTTTCC-3′) has been immobilized.
The active form of NF-jB contained in nuclear extract
specifically binds to this oligonucleotide. The primary an-
tibody used to detect NF-jB recognizes an epitope on
p65 that is accessible only when NF-jB is activated and
bound to its target DNA. A secondary HRP-conjugated
antibody provides a sensitive colorimetric readout easily
quantified by spectrophotometry. To quantify NF-jB ac-
tivation, 5 lg of nuclear extract was measured using the
Trans-AM NF-jB Kit according to the manufacturer’s
instructions (Active Motif).
Transient transfect for PPAR-c
HK-2 cells were cultured and transfected with super-
coiled PPAR-c expressive vectors pSG5hPPAR-c, which
encode a constitutively active PPAR-c (kindly provided
by Professor B. Staels, Lille, France), by electroporation
at 400 V and 100 lF with a Gene Pulser (Bio-Rad, Hemel
Hempstead, Herefordshire, UK). pSG5 vector without
insert of PPAR-c (Stratagene Europe, Amsterdam, The
Netherlands) was used as plasmid control. After electro-
poration, the cells were placed in a T75 flask with growth
medium. Approximately 24 hours after replating, cells
were replaced by fresh serum-free medium in the pres-
ence or absence of x-3 polyunsaturated fatty acids (EPA
or DHA) for 24 hours. The cells were then collected and
nuclear extracts were isolated.
Statistical analyses
In all experiments, data were evaluated for significance
by one-way analysis of variance (ANOVA) using Minitab
software. Data were considered significant at P < 0.05.
RESULTS
Both EPA and DHA at 10 lmol/L and 100 lmol/L
concentrations effectively decreased LPS-induced
(10 lg/mL) NF-jB activation (Fig.1A). The specificity
of the assay was confirmed by showing that 20 pmol/well
of the wild-type consensus oligonucleotide prevented
NF-jB activation, while the mutated consensus oligonu-
cleotide had no effect on NF-jB activation (Fig. 1B).
The MCP-1 concentration was examined by ELISA in
the supernatant of LPS-stimulated HK-2 cells (10 lg/mL
for 24 hours) in the absence or presence of various
concentrations of EPA or DHA. Both EPA and DHA
effectively decreased LPS induced MCP-1 production in
a dose-dependent manner (Fig.2A). LPS-induced MCP-1
mRNA was also suppressed by EPA and DHA (Fig. 2B).
We examined the cell viability under stimulation of high
concentration of EPA and DHA (100 lmol/L) using
trypan blue staining and lactate dehydrogenase (LDH)
measurement. The concentrations of EPA and DHA
used in this manuscript are not toxic for HK-2 cells
during 24 to 48 hours of culture.
Both EPA and DHA increased PPAR-c mRNA ex-
pression (Fig. 3A). A two- to threefold increased binding
of PPAR-c to PPRE was observed, with little difference
between EPA and DHA (Fig. 3B). The specificity of the
assay was demonstrated by showing that 40 pmol/well
of the wild-type consensus oligonucleotide prevented
PPAR-c activation, while the mutated consensus oligonu-
cleotide had no effect on PPAR-c activation (Fig. 3C).
Next, we demonstrated that the PPAR-c antagonist
BADGE abolished PPAR-c activation by EPA and DHA
in HK-2 cells (Fig. 4A). BADGE (100 lmol/L) also
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Fig. 1. Effects of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) on nuclear factor-kappaB (NF-jB) activity in lipopolysac-
charide (LPS)-stimulated human kidney-2 (HK-2) cells. (A) HK-2 cells
were pretreated in keratinocyte serum-free media (K-SFM) without
supplement but containing different concentrations of EPA, DHA for
23 hours, and then incubated for another 1 hour in the presence or
absence of 10 lg/mL LPS. Consensus nuclear extracts were prepared
and assayed using the Trans-AM enzyme-linked immunsorbent assay
(ELISA) system as described in the Methods section. (B) The wild-type
and mutated oligonucleotides were provided as a competitor for NF-jB
binding in order to monitor the specificity of the assay. Data represent
the means ± SD of four independent experiments. ∗P < 0.05 vs. LPS
induction group. OD is optical density.
removed the inhibitory effect of EPA and DHA on LPS-
induced NF-jB activation in HK-2 cells (Fig. 4B). To fur-
ther clarify the relationship between PPAR-c and NF-jB,
PPAR-c was overexpressed in HK-2 cells by transient
transfection. EPA and DHA increased PPAR-c activa-
tion in a dose-dependent manner in the pSG5 plasmid
control group (Fig. 5A). Overexpression of PPAR-c fur-
ther increased PPAR-c activation compared to the plas-
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0.00
M
CP
-1
, p
g/
µg
 p
ro
te
in
LPS10 (µg/mL)
EPA (µmol/L)
DHA (µmol/L)
− + + + + +
− − 10 100 − −
− − − − 10 100
*
*
*
*
A
18
16
14
12
10
8
6
4
2
0
M
CP
-1
 m
RN
A 
ex
pr
es
sio
n 
ra
tio
 to
 c
on
tro
l
LPS (10 µg/mL)
EPA (µmol/L)
DHA (µmol/L)
BADGE (µmol/L)
− + + + + + + +
− − 10 100 − − 100 −
− − − − 10 100 − 100
− − − − − − 100 100
•
•
•
••
•••
B
Fig. 2. Effects of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) on monocyte chemoattractant protein-1 (MCP-1) protein
levels and mRNA expression in lipopolysaccharide (LPS)-stimulated
human kidney-2 (HK-2) cells. (A) HK-2 were incubated in keratinocyte
serum-free media (K-SFM) without supplement but containing differ-
ent concentrations of EPA and DHA in the presence or absence of 10
lg/mL LPS for 24 hours. Supernatants were collected and assayed for
MCP-1 as described in the Methods section. Results are expressed as
means ± SD of four independent experiments. (B) HK-2 cells were cul-
tured in K-SFM containing 10 lg/mL LPS with different concentrations
of EPA and DHA in the absence or presence of 100 lmol/L bisphenol
A diglycidyl ether (BADGE) for 24 hours. MCP-1 mRNA was deter-
mined following the Ct protocol for real-time reverse transcription-
polymerase chain reaction (RT-PCR) as described in the Methods sec-
tion. b actin served as the housekeeper gene. ∗P < 0.05 vs. LPS induction
control; •P < 0.05 vs. LPS induction group; ••P < 0.05 vs EPA100 plus
LPS; •••P < 0.05 vs DHA 100 plus LPS.
mid control in the presence of EPA or DHA (Fig. 5A).
It also decreased LPS-induced NF-jB activation com-
pared to the plasmid control (Fig. 5B). This activation
was further decreased in the presence of EPA or DHA
(Fig. 5B).
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Fig. 3. Effects of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) on mRNA expression and activation of peroxisome
proliferator-activated receptor gamma (PPAR-c) in human kidney-2
(HK-2) cells. (A) HK-2 cells were incubated in keratinocyte serum-free
media (K-SFM) without supplement (Ctr) but containing different
concentrations of EPA and DHA for 24 hours, and troglitazone (Trog)
(10 lmol/L) was used as a positive control. PPAR-c mRNA was deter-
mined following the Ct protocol for real-time reverse transcription-
polymerase chain reaction (RT-PCR) as described in the Methods
section. b actin served as the housekeeper gene. (B) Nuclear extracts
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Fig. 4. Effects of the bisphenol A diglycidyl ether (BADGE) on the
activity of peroxisome proliferator-activated receptor-gamma (PPAR-
c) and nuclear factor-kappaB (NF-jB) in eicosapentaenoic acid (EPA)
or docosahexaenoic acid (DHA)-treated human kidney-2 (HK-2) cells.
HK-2 cells were incubated in keratinocyte serum-free media (K-SFM)
without supplement but containing 100 lmol/L of EPA, DHA, and
BADGE for 24 hours (A) or for 23 hours and then incubated for an-
other 1 hours in the presence or absence of 10lg/mL lipopolysaccharide
(LPS) (B). Nuclear extracts were prepared for measurements of PPAR-
c or NF-jB activation, respectively. Nuclear extracts were assayed as
described in the Methods section. Data represent the means ± SD of
four independent experiments. ∗P < 0.05 vs. vehicle control; ∗∗P < 0.05
vs. EPA alone; ∗∗∗P < 0.05 vs. DHA alone; •P < 0.05 vs. LPS induction
group; ••P < 0.05 vs. EPA plus LPS; •••P < 0.05 vs. DHA plus LPS. OD
is optical density.
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
were prepared and assayed as described in the Methods section. (C) The
wild-type and mutated oligonucleotide were provided as a competitor
for PPAR-c binding in order to monitor the specificity of the assay. Data
represent the means ± SD of four independent experiments. ∗P < 0.05
vs. vehicle control group; •P < 0.05 vs. vehicle control group; ∗∗P < 0.05
vs. EPA alone. OD is optical density.
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Fig. 5. Effects of over-expression of peroxisome proliferator-activated
receptor-gamma (PPAR-c) on activation of PPAR-c and lipopolysac-
charide (LPS)-induced nuclear factor-kappaB (NF-jB) activation in
human kidney-2 (HK-2) cells. HK-2 cells were transiently transfected
with pSG5 plasmid control () or pSG5hPPAR-c () using electropo-
ration as described in the Methods section. Both transiently transfected
HK-2 cells were incubated in keratinocyte serum-free media (K-SFM)
without supplement but containing different concentrations of eicos-
apentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 24 hours.
Nuclear extracts were prepared for measurement of PPAR-c activation
(A). Both transiently transfected HK-2 cells were pretreated in K-SFM
without supplement but containing 100 lmol/L of EPA and DHA for 23
hours and then incubated for another 1 hour in the presence or absence
of 10 lg/mL LPS. Nuclear extracts were prepared for measurement of
NF-jB activation (B). Nuclear extracts were assayed using the Trans-
AM enzyme-linked immunosorbent assay (ELISA) system as described
in the Methods section. Data represent the means ± SD of four indepen-
dent experiments. ∗P < 0.05 vs. corresponding vehicle control; ∗∗P <
0.05 vs. pSG5 plamid control; ∗∗∗P < 0.001 vs. pSG5 plamid control;
•P < 0.05 vs. corresponding LPS induction group; ••P < 0.05 vs. pSG5
plasmid control. OD is optical density.
DISCUSSION
Despite increasing evidence of the beneficial effect of
fish oil, little is known concerning the mechanisms of
action of its fatty acid components. Pathogenic mecha-
nisms that may be affected by fish oil therapy include
proliferation of glomerular cells, infiltration of inflam-
matory cells, and production of inflammatory mediators.
Recently, Grande et al [26] demonstrated that x-3 PUFAs
can be incorporated into renal tissue. They also demon-
strated that the x-3 PUFAs in fish oil significantly in-
hibits proliferation of cultured mesangial cells in vitro
[26]. In vivo experiments have shown that fish oil reduces
glomerular cell proliferation, a-smooth muscle actin ex-
pression, and proteinuria in antithymocyte serum (ATS)
glomerulonephritis. This information is crucial for the ra-
tional use and refinement of pharmacotherapy with fish
oil and/or its components for IgAN and other mesangial
proliferative glomerulonephropathies.
Although mesangial cell proliferation is a central fea-
ture of IgAN, evidence suggests that the accumulation
of extracellular matrix proteins in the cortical intersti-
tium is a consistent feature of chronic glomerular dis-
eases and a strong determinant of IgAN and other renal
diseases [27]. Injury to PTCs and interstitial inflamma-
tion have been proposed as prerequisites for the devel-
opment of matrix deposition and interstitial fibrosis [14,
28]. There are also reports that dietary enrichment with
fish-oil could decrease urinary excretion of N-acetyl-beta-
D-glucosaminidase (a marker of tubular injury) and pro-
tect renal function in proteinuric patients with primary
glomerulopathies [29]. Increasing evidence suggests that
MCP-1 may have an important role in the regulation
of interstitial inflammation and possibly other processes
related to matrix deposition [15, 30]. Our initial exper-
iments demonstrated that both EPA and DHA inhibit
LPS-induced MCP-1 production and mRNA expression
in HK-2 cells. Both EPA and DHA also significantly in-
hibit LPS-induced NF-jB activation in a dose-dependent
manner. This suggests that x-3 PUFAs inhibit inflamma-
tory responses and may have a protective effect on PTC.
We then investigated the molecular mechanism by
which EPA and DHA inhibit NF-jB activation and MCP-
1 expression. This could occur through several pathways.
One potential mechanism may be through competi-
tion with arachidonic acid, a substrate for the lipoxy-
genase and cyclooxygenase pathways. The reduction of
arachidonic acid derived products may reduce glomerular
and interstitial inflammation, mesangial cell contractility,
platelet aggregation, and vasoconstriction in response to
renal injury [31]. x-3 PUFAs may also directly inhibit pro-
duction of the proinflammatory cytokines IL-1 and TNF-
a by mononuclear cells although the mechanism remains
unclear [32]. Another important mechanism by which x-
3 PUFAs may act as anti-inflammatory agents is by the
activation of PPARs which have been demonstrated to
inhibit production of proinflammatory cytokines, such as
TNF and IL-6 [33].
Our results demonstrate that there was constitutive
mRNA expression and activation of PPAR-c in HK-2
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cells, and that this was increased by both EPA and DHA.
This suggests that EPA and DHA may inhibit inflam-
matory responses via activation of PPAR-c. To provide
further evidence for this mechanism, we investigated
the effect of a PPAR-c antagonist on the activation of
PPAR-c and NF-jB. BADGE is a high-affinity ligand
for PPAR which has no apparent ability to activate the
transcriptional activity of PPAR-c activation; therefore,
it can antagonize the ability of a ligand to activate PPAR-
c [34]. We demonstrated that BADGE (100 lmol/L)
not only abolished the PPAR-c activation by EPA and
DHA, but also abolished the inhibitory effect of EPA
and DHA on LPS-induced activation of NF-jB in HK-2
cells. However, we cannot exclude the possibility of an
active metabolite or metabolites of EPA and DHA act-
ing as a PPAR ligand in mediating the anti-inflammatory
effect. To further clarify the relationship between PPAR-
c and NF-jB, PPAR-c was overexpressed in HK-2 cell
by transient transfection. Active NF-jB was decreased
in transfected cells and both EPA and DHA effectively
further decreased LPS-induced NF-jB activity compared
to the untransfected cells. Taken together, these find-
ings strongly suggest that anti-inflammatory activity of
x-3 PUFAs in HK-2 cells is, at least in part, mediated
through PPAR-c activation. Evidence for this also comes
from studies demonstrating that ligand-activated PPAR-
c can inhibit NF-jB activity through direct interactions
with the p65 subunit of NF-jB or increasing synthesis of
the NF-jB inhibitor, IjB [35].
CONCLUSION
Both EPA and DHA are potent inhibitors of inflam-
matory responses in HK-2 cells. The effects of EPA and
DHA are mediated by activation of PPAR-c, which is re-
sponsible for the down-regulation of NF-jB activity. x-3
PUFAs may represent a class of naturally occurring, low-
toxicity, PPAR ligands with potent anti-inflammatory
properties.
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